{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:24:37Z","timestamp":1778243077364,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.pupt.2010.01.003","type":"journal-article","created":{"date-parts":[[2010,1,19]],"date-time":"2010-01-19T05:57:57Z","timestamp":1263880677000},"page":"165-171","source":"Crossref","is-referenced-by-count":91,"title":["Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design"],"prefix":"10.1016","volume":"23","author":[{"given":"Peter J.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgo","family":"Magnussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2010.01.003_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/10543400600614742","article-title":"Adaptive designs in clinical drug development \u2013 an Executive Summary of the PhRMA Working Group","volume":"16","author":"Gallo","year":"2006","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.pupt.2010.01.003_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-3-11","article-title":"Adaptive design methods in clinical trials \u2013 a review","volume":"3","author":"Chow","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pupt.2010.01.003_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1185\/03007990802675096","article-title":"24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol","volume":"25","author":"Bauwens","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pupt.2010.01.003_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.rmed.2008.02.001","article-title":"A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison","volume":"102","author":"Rennard","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2010.01.003_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.pupt.2006.09.001","article-title":"Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial","volume":"20","author":"Beier","year":"2007","journal-title":"Pulm Pharmacol Ther"},{"issue":"Suppl. 53","key":"10.1016\/j.pupt.2010.01.003_bib6","article-title":"Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium","volume":"34","author":"Fogarty","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2010.01.003_bib7","article-title":"Safety and tolerability of indacaterol over 52 weeks of treatment in COPD","volume":"179","author":"Chung","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2010.01.003_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002876.pub2","article-title":"Inhaled tiotropium for stable chronic obstructive pulmonary disease","volume":"2","author":"Barr","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pupt.2010.01.003_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/thx.2006.063271","article-title":"Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis","volume":"61","author":"Barr","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2010.01.003_bib10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2010.01.003_bib11","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1378\/chest.121.4.1058","article-title":"Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD","volume":"121","author":"Rossi","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2010.01.003_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1159\/000091996","article-title":"Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD","volume":"73","author":"Richter","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2010.01.003_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2010.01.003_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2010.01.003_bib15","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1152\/jappl.2000.88.6.1989","article-title":"Mechanisms for isolated volume response to a bronchodilator in patients with COPD","volume":"88","author":"Cerveri","year":"2000","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pupt.2010.01.003_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1183\/09031936.01.00216501","article-title":"Evaluation of bronchodilator responses in patients with \u2018irreversible\u2019 emphysema","volume":"18","author":"O'Donnell","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2010.01.003_bib17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1378\/chest.121.4.1042","article-title":"Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation","volume":"121","author":"Newton","year":"2002","journal-title":"Chest"},{"issue":"Suppl. 53","key":"10.1016\/j.pupt.2010.01.003_bib18","first-page":"E4350","article-title":"Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol","volume":"34","author":"Dahl","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2010.01.003_bib19","author":"U.S. Department of Health and Human Services Food and Drug Administration"},{"key":"10.1016\/j.pupt.2010.01.003_bib20","author":"U.S. Department of Health and Human Services Food and Drug Administration"},{"key":"10.1016\/j.pupt.2010.01.003_bib21","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/10543400701643764","article-title":"Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop","volume":"17","author":"Krams","year":"2007","journal-title":"J Biopharm Stat"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553910000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553910000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T02:56:16Z","timestamp":1558752976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553910000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1094553910000143"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2010.01.003","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}